Neither adjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF) nor peptide vaccination significantly improved relapse-free or overall survival in patients with high-risk resected melanoma, although GM-CSF may be beneficial in patients with resected visceral metastases, a large phase III trial indicated.
